Compare Brookfield Renewable (BEP) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brookfield Renewable vs Incyte Corporation — how do they compare? Brookfield Renewable trades at $28.85 (market cap $8.80B), while Incyte Corporation trades at $116.4 (market cap $23.63B). The key difference: Incyte Corporation is far larger — about 2.7× Brookfield Renewable's market cap, and Brookfield Renewable pays a 5.36% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Brookfield Renewable for 19 Days and Incyte Corporation for 33 Days on average.
| BEP | INCY | |
|---|---|---|
Market Cap | $8.80B | $23.63B |
Volume | 2,091,675 | 2,230,873 |
Sector | Utilities | Health |
52-Week High | $37.31 | $129.93 |
52-Week Low | $26.67 | $90.18 |
Typical Hold Time | 19 Days | 33 Days |
Enterprise Value | $43.39B | $19.14B |
Dividend Yield | 5.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BEP trades at $29.27, up 2.56% today, but remains in a bearish technical trend below key resistance levels. The company reported negative net income of -$37M for 2025 with declining profitability margins, though revenue remains stable at $6.41B. Recent corporate simplification approval and focus on AI power demand provide potential catalysts, while analyst consensus remains strongly bullish with a $37.83 price target.
The stock faces headwinds from consecutive earnings misses and negative profitability metrics, but strong institutional support and strategic positioning in renewable energy infrastructure offer long-term growth potential. Key risks include execution challenges in capital-intensive projects and sensitivity to interest rate changes affecting financing costs.
Incyte (INCY) trades at $117.39, up 3.6% with strong earnings beats in Q1 and Q2 2026. The stock shows neutral technical signals with bullish moving averages, while fundamentals reveal robust profitability with 92.6% gross margins and 27.7% net income margin. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives.
Outlook remains positive with analyst consensus target of $136.53 (16% upside), though Q3 2026 faces an expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B non-JAKAFI sales target. Institutional sentiment leans bullish with 52% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Brookfield Renewable
Brookfield Renewable owns and operates renewable power and sustainable solutions businesses. Its portfolio includes hydroelectric, wind, solar, distributed energy, and energy storage assets.
Read more on BEP →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
